Showing results (431-440 of 467) with videos related to

Sort By:
Pageof 47
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 18, 2012
Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brainMichele J Writer, Panagiotis G Kyrtatos, Alison S Bienemann, et al.
The Journal of Pediatrics|April 6, 2015
Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemiaD Meeike Kusters, Maria Caceres, Mauricio Coll, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2001
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group studyE S Lowe, B J Kitchen, G Erdmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO TrialJung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Head & Neck|October 30, 2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinomaVasiliki A Papadimitrakopoulou, Steven J Frank, Ezra W Cohen, et al.
Scientific Reports|May 19, 2023
Correcting bias in cardiac geometries derived from multimodal images using spatiotemporal mappingDebbie Zhao, Charlène A Mauger, Kathleen Gilbert, et al.
The Journal of Antibiotics|May 29, 1999
Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vacciniiJ Qian-Cutrone, T Ueki, S Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
The Journal of Clinical Investigation|March 11, 2009
Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heartMadhu V Singh, Ann Kapoun, Linda Higgins, et al.
The Journal of Emergency Medicine|January 14, 2023
Impact of Race and Ethnicity on Emergency Medical Services Administration of Opioid Pain Medications for Injured ChildrenDaniel K Nishijima, Daniel J Tancredi, Kathleen M Adelgais, et al.
Pageof 47